NCT02320032 - An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia | Biotech Hunter

Enrollment

140

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions

Schizophrenia

Interventions

DRUG

Aripiprazole Lauroxil

Gluteal IM injection, given once every 4 to 8 weeks

Trial Locations (16)

8053

Alkermes Investigational Site, Marlton

20016

Alkermes Investigational Site, Washington D.C.

30308

Alkermes Investigational Site, Atlanta

32751

Alkermes Investigational Site, Maitland

33161

Alkermes Investigational Site, Lauderhill

33334

Alkermes Investigational Site, Oakland Park

33613

Alkermes Investigational Site, Tampa

34748

Alkermes Investigational Site, Leesburg

60169

Alkermes Investigational Site, Hoffman Estates

60640

Alkermes Investigational Site, Chicago

63118

Alkermes Investigational Site, St Louis

72211

Alkermes Investigational Site, Little Rock

75243

Alkermes Investigational Site, Dallas

78754

Alkermes Investigational Site, Austin

90703

Alkermes Investigational Site, Cerritos

92845

Alkermes Investigational Site, Garden Grove